Raymond James Downgrades ARS Pharmaceuticals to Outperform, Lowers Price Target to $17

Benzinga · 3d ago
Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28 to $17.